Amgenvs.Vertex Pharmaceuticals
AMGN vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Amgen is about 1.7× larger than Vertex Pharmaceuticals by market cap; Amgen trades at the lower P/E (25.2 vs 29.0); year to date, Amgen leads (+26.2% vs +11.0%).
Side by side
| AMGN | VRTX | |
|---|---|---|
| Market cap | $220B | $128B |
| Price | $414.87 | $510.08 |
| Today | +1.8% | +1.4% |
| Return YTD | +26.2% | +11.0% |
| Return 1Y | +39.8% | +19.5% |
| Since June 26, 2026 | +15.8% | +3.8% |
| P/E | 25.2 | 29.0 |
| P/S | 5.8 | 10.1 |
| P/B | 18.8 | 6.3 |
Data as of 2026-10-09 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
AmgenAMGN
Long-established in biotech, with oncology and haematology at the centre of the portfolio, immunology beside it and a line in bone disease. MariTide is the obesity candidate in the pipeline.
Full AMGN profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More AMGN & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.